- Profile
- prev
- next
General
-
Headquarters
San Francisco, California, United States of America
-
Founders & Team
Keith Leonard, Nathaniel E. David
-
Year Founded
2009
-
Number of employees
100
-
Company type
Public company
-
Stock Ticker
NASDAQ:UBX
-
Funding stage
IPO
-
Total funding ($M)
210
-
Investors
The Longevity Fund, Founders Fund, ARCH Ventures
Technical Details
-
Aging Target
Cellular senescence
-
Disease indication
Osteoarthritis, Eye disease, Lung disease, Dementia
-
Product modality
small molecule drugs
-
Clinical stage
Phase 1 Trials
-
Product names
UBX0101, UBX1325
About
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include senolytics (drugs targeting senescent cells) UBX0101 that is in Phase 2 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.